A Phase 1b study demonstrates that combining SBRT with the bispecific antibody cadonilimab (PD-1/CTLA-4) is safe and effective for refractory solid tumors, yielding a 23.8% response rate and 7.2-month median PFS in patients who failed multiple prior lines of therapy.